4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

NEWS ROOM

February 25, 2019

Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its oper...

January 3, 2018

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announc...

December 19, 2017

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced tod...

Please reload

ARCHIVE
Please reload

SEARCH BY TAGS
Please reload

FOLLOW US